ScoreWhy is HLS Therapeutics, Inc. ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.46 times
- Poor long term growth as Net Sales has grown by an annual rate of 0.66% and Operating profit at 10.74% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.46 times
- The company has reported losses. Due to this company has reported negative ROE
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -12.68%, its profits have risen by 54%
3
Below par performance in long term as well as near term
- Along with generating -12.68% returns in the last 1 year, the stock has also underperformed S&P/TSX 60 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is HLS Therapeutics, Inc. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
HLS Therapeutics, Inc.
-12.68%
1.00
22.35%
S&P/TSX 60
29.6%
2.31
12.81%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
0.66%
EBIT Growth (5y)
10.74%
EBIT to Interest (avg)
-1.32
Debt to EBITDA (avg)
3.40
Net Debt to Equity (avg)
0.68
Sales to Capital Employed (avg)
0.43
Tax Ratio
28.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.57%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.67
EV to EBIT
-31.68
EV to EBITDA
7.28
EV to Capital Employed
1.44
EV to Sales
2.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.53%
ROE (Latest)
-15.40%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CAD 25.65 MM
NET PROFIT(HY)
Higher at CAD -4.17 MM
ROCE(HY)
Highest at -15.97%
DEBT-EQUITY RATIO
(HY)
Lowest at 53.96 %
DEBTORS TURNOVER RATIO(HY)
Highest at 6.83 times
-3What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 6.45% (YoY
CASH AND EQV(HY)
Lowest at CAD 33.27 MM
NET SALES(Q)
Lowest at CAD 17.65 MM
Here's what is working for HLS Therapeutics, Inc.
Net Profit
Higher at CAD -4.17 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CAD MM)
Net Profit
At CAD -4.17 MM has Grown at 56.92%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (CAD MM)
Operating Cash Flow
Highest at CAD 25.65 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CAD MM)
Debt-Equity Ratio
Lowest at 53.96 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 6.83 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for HLS Therapeutics, Inc.
Net Sales
Lowest at CAD 17.65 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (CAD MM)
Cash and Eqv
Lowest at CAD 33.27 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 6.45% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
